Purchase of own shares and PDMR Dealing

 22nd Nov 2018

Download the full announcement


EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, announces an update to its prior announcement on 14 November 2018 in relation to the Buy-Back. The Company confirms that on 21 November 2018, it purchased 570,954 of its ordinary shares on the London Stock Exchange at a price of 27.00 pence per share. The purchased shares will be cancelled.


Aggregated information:

Date of purchase:

21 November 2018

Issuer name:

EKF Diagnostics Holdings plc



Number of ordinary shares purchased:


Volume weighted average price paid per share:

27.00 pence

Trading venue

London Stock Exchange


Transaction details:

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), a full breakdown of the individual trades made by N+1 Singer on behalf of the Company as part of the Buy-Back programme is detailed below:


Number of shares purchased

Transaction price (GBp)

Time of transaction

Trading venue










Total Voting Rights

Following the cancellation, the Company’s total issued share capital will consist of 455,163,766 shares of 1 pence each (“Ordinary Shares”) with one voting right per share. The Company will not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 455,163,766.


The above figure of 455,163,766 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.


PDMR dealing

As part of the Buy-Back and within the above aggregate purchase, EKF acquired 170,954 ordinary shares at a price of 27.00 pence per share from Harwood Capital LLP ("Harwood") as investment manager to Oryx International Growth Fund Limited ("Oryx"). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in Oryx.  As stated in the announcement of 14 November, Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.


Following the above sale of ordinary shares by Oryx to the Company, Mr. Mills’ aggregate indirect interest in the Company is 136,284,130 ordinary shares, representing 29.94 per cent. of the total voting rights in EKF.  38,284,130 of these shares are held by Oryx and the balance by North Atlantic Smaller Companies Investment Trust PLC (“NASCIT”), an investment trust to which Harwood acts as an investment adviser and of which Christopher Mills is a director and shareholder.


Additional disclosures relating to this PDMR dealing are detailed below.


For further information please contact:


EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Julian Baines, CEO
Richard Evans, FD and COO

Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker)

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)

Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303


About EKF Diagnostics Holdings plc

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.